glp-1 receptor agonist type 1 diabetes randomized trial SGLT2i and RA therapy in and reno-vascular outcomes: a real-world study | Diabetologia New Developments in Pharmacological Treatment

Wall, B et al

Weve entered into an agreement with Omeros Corporation to acquire and license zaltenibart (OMS906) a clinical-stage MASP-3 inhibitor with best-in-class potential across multiple rare blood and kidney disorders

Injection speed and depth optimization Speed and depth deserve additional emphasis because they are the most controllable variables and the most common sources of preventable reactions

Thanks to its convenient format, it easily fits into your daily routine and can be taken anywhere

Participants showed significant reductions in fatigue, improvements in feelings of liveliness, and enhanced cognitive performance measured by psychomotor vigilance testing